Study #2017-0618
A PHASE 1/2 MULTICENTER, OPEN-LABEL STUDY TOASSESS THE SAFETY, PHARMACOKINETICS ANDEFFICACY OF CC-92480 MONOTHERAPY AND INCOMBINATION WITH DEXAMETHASONE INSUBJECTS WITH RELAPSED AND REFRACTORYMULTIPLE MYELOMA
MD Anderson Study Status
Enrolling
Treatment Agent
CC-92480, Dexamethasone
Description
This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM). RRMM patient previously treated with at least 3 prior regimens including lenalidomide or pomalidomide, a proteasome inhibitor and a CD38 antibody will be eligible.
Information and next steps
Disease:
Multiple Myeloma
Study phase:
I/II
Physician name:
Robert Orlowski
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.